Your browser is no longer supported. Please, upgrade your browser.
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E21.61 EPS (ttm)18.47 Insider Own20.40% Shs Outstand109.82M Perf Week-1.76%
Market Cap43.83B Forward P/E13.88 EPS next Y28.76 Insider Trans-0.61% Shs Float81.56M Perf Month9.74%
Income2.12B PEG2.62 EPS next Q6.42 Inst Own71.30% Short Float3.54% Perf Quarter17.33%
Sales7.86B P/S5.57 EPS this Y-10.80% Inst Trans1.62% Short Ratio3.65 Perf Half Y34.83%
Book/sh101.55 P/B3.93 EPS next Y4.15% ROA15.50% Target Price416.67 Perf Year-5.53%
Cash/sh29.27 P/C13.64 EPS next 5Y8.25% ROE20.70% 52W Range271.37 - 442.00 Perf YTD6.30%
Dividend- P/FCF21.91 EPS past 5Y44.00% ROI16.10% 52W High-10.19% Beta1.36
Dividend %- Quick Ratio3.20 Sales past 5Y22.80% Gross Margin90.10% 52W Low46.29% ATR10.76
Employees8100 Current Ratio3.70 Sales Q/Q12.50% Oper. Margin28.10% RSI (14)61.06 Volatility2.01% 2.78%
OptionableYes Debt/Eq0.06 EPS Q/Q4.00% Profit Margin26.90% Rel Volume0.41 Prev Close399.14
ShortableYes LT Debt/Eq0.06 EarningsFeb 06 BMO Payout0.00% Avg Volume790.76K Price396.98
Recom2.40 SMA206.93% SMA506.26% SMA20022.24% Volume208,897 Change-0.54%
Feb-11-20Upgrade Argus Hold → Buy $430
Dec-24-19Initiated Raymond James Mkt Perform
Dec-16-19Downgrade Evercore ISI Outperform → In-line
Dec-13-19Upgrade Credit Suisse Neutral → Outperform $400
Nov-12-19Initiated SunTrust Hold $360
Nov-07-19Upgrade Citigroup Neutral → Buy $340 → $420
Oct-17-19Resumed BofA/Merrill Neutral $325
Sep-23-19Upgrade Guggenheim Neutral → Buy $355 → $403
Aug-07-19Upgrade Robert W. Baird Neutral → Outperform $410
Jun-18-19Downgrade Argus Buy → Hold
May-23-19Resumed Citigroup Neutral
May-21-19Initiated Credit Suisse Neutral $336
May-08-19Reiterated Canaccord Genuity Hold $408 → $353
Jan-04-19Upgrade Guggenheim Neutral → Buy
Oct-01-18Initiated Cantor Fitzgerald Neutral $415
May-04-18Reiterated Canaccord Genuity Hold $356 → $304
Apr-09-18Downgrade Raymond James Outperform → Mkt Perform
Feb-21-18Downgrade Canaccord Genuity Buy → Hold $522 → $356
Jan-09-18Reiterated Citigroup Neutral $380 → $388
Dec-01-17Downgrade Citigroup Buy → Neutral $480 → $380
Feb-21-20 10:34AM  Top Ranked Momentum Stocks to Buy for February 21st Zacks
Feb-19-20 12:20PM  Surging Earnings Estimates Signal Upside for Regeneron (REGN) Stock Zacks
09:42AM  Sanofi, J&J Join Forces With BARDA for Coronavirus Vaccine Zacks
Feb-18-20 01:01PM  The Wuhan Virus and Research-Focused Biotech Companies GuruFocus.com
Feb-14-20 09:02AM  Vertex Is the Top Big Biotech, According to Citi. 3 More Stocks It Says to Buy. Barrons.com
Feb-13-20 10:45AM  Prothena (PRTA) Q4 Loss Narrower Than Expected, Revenues Beat Zacks
Feb-12-20 11:44PM  Edited Transcript of REGN earnings conference call or presentation 6-Feb-20 1:00pm GMT Thomson Reuters StreetEvents
Feb-11-20 11:40AM  REGN vs. HZNP: Which Stock Is the Better Value Option? Zacks
10:41AM  Regeneron Pharmaceuticals, Inc. Full-Year Results: Here's What Analysts Are Forecasting For Next Year Simply Wall St.
09:32AM  Sanofi and Regeneron Have a Likely Blockbuster in Their Dermatitis and Asthma Drug, Analyst Says Barrons.com
Feb-10-20 09:18AM  Regeneron Reports Positive Eylea Data From Late-Stage Study Zacks
Feb-08-20 05:00PM  EYLEA® (aflibercept) Injection Reduced Risk of Developing Vision-Threatening Events by 75% After Two Years in Patients with Diabetic Retinopathy PR Newswire
Feb-07-20 04:50PM  The No. 1 Biotech Stock Just Squashed Earnings Views Here's Why Investor's Business Daily
11:30AM  Is Regeneron Pharmaceuticals (REGN) Outperforming Other Medical Stocks This Year? Zacks
09:25AM  Alnylam's (ALNY) Q4 Earnings Miss Estimates, Sales Beat Zacks
Feb-06-20 03:44PM  Stock Market in the Green on Thursday GuruFocus.com
11:11AM  Sanofi (SNY) Q4 Earnings Top, Sales Miss, Dupixent Strong Zacks
10:40AM  Regeneron's (REGN) Q4 Earnings & Sales Surpass Estimates Zacks
08:37AM  Regeneron likely to test treatments in coronavirus patients in few months Reuters
07:45AM  Regeneron (REGN) Q4 Earnings and Revenues Surpass Estimates Zacks
06:30AM  Regeneron Reports Fourth Quarter and Full Year 2019 Financial and Operating Results PR Newswire
06:00AM  Regeneron Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
01:32AM  Regeneron Pharma Earnings, Revenue Beat in Q4 Investing.com
Feb-05-20 11:17AM  Regeneron Expands Agreement to Develop Coronavirus Therapy Zacks
11:15AM  Biotech Stock Roundup: Earnings Updates From VRTX, AMGN, GILD; AIMT Gains FDA Nod Zacks
10:00AM  Biotech Stocks Ran Up In 2019 Who's Leading The Pack For 2020? Investor's Business Daily
08:32AM  Should You Buy Regeneron (REGN) Ahead of Earnings? Zacks
Feb-04-20 10:19AM  What's in Store for Innoviva (INVA) This Earnings Season? Zacks
09:00AM  Regeneron Announces Expanded Collaboration with HHS to Develop Antibody Treatments for New Coronavirus PR Newswire
08:50AM  Drugmaker Regeneron working with U.S. HHS to develop coronavirus treatment Reuters
Feb-03-20 10:18AM  Factors Setting the Tone for Bristol-Myers (BMY) Q4 Earnings Zacks
10:09AM  Is a Disappointment in Store for Glaxo's (GSK) Q4 Earnings? Zacks
10:06AM  Will Eylea & Dupixent Drive Regeneron's (REGN) Q4 Earnings? Zacks
Jan-31-20 09:17AM  Will Strong HIV Sales Drive Gilead's (GILD) Q4 Earnings? Zacks
Jan-30-20 12:31PM  Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
Jan-29-20 02:59PM  Parnassus Endeavor Fund Exits Biogen, Trims Regeneron GuruFocus.com
10:09AM  Novartis (NVS) Earnings and Revenues Miss Estimates in Q4 Zacks
09:59AM  Biotech Stock Roundup: EPZM Drug Gets FDA Nod, XLRN & HEPA Surge on Study Data Zacks
Jan-28-20 10:39AM  Regeneron & Sanofi's sBLA for Dupixent Accepted by the FDA Zacks
10:35AM  Can CF Drugs Drive Growth for Vertex (VRTX) in Q4 Earnings? Zacks
10:31AM  Lilly's Olumiant Meets Primary Goal in Dermatitis Study Zacks
01:10AM  U.S. FDA regulator gives new priority review for Sanofi and Regeneron's Dupixent Reuters
12:59AM  FDA Accepts for Priority Review Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis PR Newswire
Jan-27-20 09:08AM  3 Biotech Stocks Nearing Support Investopedia
03:26AM  Regeneron's Pullback Amid Market Weakness Could Lead to Buying Opportunity TheStreet.com
Jan-23-20 11:40AM  REGN vs. HZNP: Which Stock Is the Better Value Option? Zacks
09:31AM  A Tale of 3 Healthcare Stocks 2 to Buy, and 1 to Sell TipRanks
Jan-22-20 12:01PM  Forty of the Nation's Brightest Young Scientists Named Finalists in Regeneron Science Talent Search 2020 PR Newswire
09:50AM  With A Return On Equity Of 20%, Has Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Management Done Well? Simply Wall St.
Jan-21-20 09:30AM  Is Regeneron Pharmaceuticals (REGN) a Worthy Stock to Pick? Zacks -5.76%
Jan-17-20 08:19AM  Will J&J (JNJ) Roll Out Pharma Q4 Earnings With a Beat? Zacks
Jan-16-20 06:00AM  Why Regeneron bought a day care center in North Greenbush American City Business Journals
Jan-13-20 09:08AM  Lilly to Buy Dermira for $1.1B, Add Phase III Eczema Candidate Zacks
Jan-10-20 05:00PM  Regeneron's Phase II Candidate Promising in Primary Analysis Zacks
09:50AM  Lilly Says Its Buying a Biotech With a Dermatitis Drug. Investors Have Other Ideas. Barrons.com
07:00AM  Regeneron to Report Fourth Quarter and Full Year 2019 Financial and Operating Results and Host Conference Call and Webcast on February 6, 2020 PR Newswire
Jan-09-20 09:20AM  4 Things to Pay Attention to at the J.P. Morgan Health-Care Conference Next Week Barrons.com
07:00AM  Regeneron Announces Encouraging Garetosmab Phase 2 Results in Patients with Ultra-Rare Debilitating Bone Disease PR Newswire
Jan-08-20 02:02PM  Publication Highlights Regeneron's Costimulatory Bispecific Antibodies, an Emerging Class of Cancer Immunotherapy PR Newswire
Jan-06-20 12:10PM  Can Regeneron (REGN) Keep the Earnings Surprise Streak Alive? Zacks
Jan-02-20 01:05PM  Top 5 Best-Performing Stocks of the Past Decade GuruFocus.com
Dec-30-19 10:23AM  Alnylam Stock Up More Than 61% YTD on Pipeline Progress Zacks
Dec-28-19 04:22PM  These are the 20 best-performing stocks of the past decade, and some of them will surprise you MarketWatch
Dec-26-19 11:11AM  2019 Review: Most Favored Hedge Fund Stocks vs. Regeneron Pharmaceuticals Inc (REGN) Insider Monkey
Dec-24-19 09:03AM  What to Expect from Amgen and Regeneron Stock in 2020, According to an Analyst Barrons.com
Dec-20-19 04:47PM  The Decades 10 Best-Performing Stocks and Which Ones Have Room to Run Barrons.com
10:04AM  Merck's Ebola Vaccine Ervebo Gets Approval in United States Zacks
09:03AM  Here's Why I Think Regeneron Pharmaceuticals (NASDAQ:REGN) Might Deserve Your Attention Today Simply Wall St.
07:00AM  Regeneron Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-19-19 10:18AM  Biotech Stock Outlook: M&A Activity Retains Growth Streak Zacks
Dec-18-19 08:50AM  Alnylam's Kidney Disease Drug Succeeds in Late Stage Study Zacks
Dec-16-19 01:43PM  Amarins fish-oil pill now available to millions more patients. But its still no Lipitor MarketWatch
12:01PM  Regeneron Stock Is Downgraded. Analyst Cites Tough Competition From a Novartis Drug. Barrons.com
08:38AM  Amarin Gains on FDA Approval of Vascepa Label Expansion Zacks
07:37AM  Novartis Gets Positive CHMP Opinion for Wet AMD Drug Beovu Zacks
Dec-13-19 09:50PM  Edited Transcript of REGN earnings conference call or presentation 5-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
10:29AM  Biotech Stocks Are Poised to Rise in 2020, Analyst Says. Here Is His Top Pick. Barrons.com
Dec-12-19 12:46PM  Regeneron Pharmaceutical Reaches 80-Plus Relative Strength Rating Benchmark Investor's Business Daily
10:15AM  Society for Science & the Public Announces Regeneron as New Title Sponsor of the International Science and Engineering Fair PR Newswire
07:00AM  Regeneron and Cold Spring Harbor Laboratory Unveil New Dedicated Laboratories for Student Science Education PR Newswire
Dec-11-19 09:41AM  Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar Zacks
09:14AM  Sanofi, Regeneron to Amend Agreement for Kevzara & Praulent Zacks
Dec-10-19 04:08PM  Why This Pharmaceutical Stock Broke Out Bullishly In Early Action Investor's Business Daily
12:28PM  Regeneron Shares Swing On Sanofi's Hint At Sale Of Ownership Stake, Amendments To Drug Collaborations Benzinga
09:03AM  Regeneron shares fall on Sanofi's new direction MarketWatch
08:55AM  Sanofi Unveils Growth Strategy, Ends Diabetes & CV Research Zacks
08:29AM  Regeneron and Sanofi Announce Intent to Restructure Antibody Collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab) PR Newswire
08:06AM  Dow Jones Futures: Stock Market, Apple On China Trade War Watch; Boeing, MongoDB, Stitch Fix Move On News Investor's Business Daily
06:38AM  Sanofis CEO Quits Diabetes as Cancer Breakthroughs Beckon Bloomberg
Dec-09-19 04:31PM  Regeneron Reports Initial Data for Multiple Myeloma Drug Zacks
Dec-08-19 09:00AM  First Clinical Data for REGN5458 (BCMAxCD3) Show Positive Preliminary Results in Multiple Myeloma PR Newswire
Dec-07-19 08:35AM  The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling Benzinga
Dec-06-19 09:21AM  Regeneron Reports Positive Data on Rare Blood Disorder Drug Zacks
Dec-05-19 11:31AM  Why Is Regeneron (REGN) Up 14% Since Last Earnings Report? Zacks
07:00AM  Regeneron Announces Positive Topline Phase 2 Data with Anti-C5 Antibody Pozelimab in Patients with a Rare Blood Disorder PR Newswire
Dec-04-19 08:33PM  Did Hedge Funds Drop The Ball On Regeneron Pharmaceuticals Inc (REGN) ? Insider Monkey
09:11AM  The stock market's biggest winners and losers of the past decade Yahoo Finance
Dec-03-19 07:31AM  Regeneron Pharmaceuticals Could Surprise on the Upside With Its Quant Buy Signal TheStreet.com
Nov-29-19 09:34AM  Alnylam Gets Second Product Approval Amid Stiff Competition Zacks
08:48AM  China Negotiates Bargain Prices With Big Pharma Barrons.com
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services for the development of new treatments combating the coronavirus. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tessier-Lavigne MarcDirectorFeb 13Option Exercise53.0814,279757,94411,109Feb 14 04:10 PM
Tessier-Lavigne MarcDirectorFeb 13Sale400.0114,2795,711,7111,830Feb 14 04:10 PM
Landry Robert EEVP Finance CFOFeb 13Sale400.0510742,80624,973Feb 14 04:10 PM
Landry Robert EEVP Finance CFOFeb 12Option Exercise272.70500136,35025,473Feb 14 04:10 PM
GOLDSTEIN JOSEPH LDirectorFeb 07Sale382.831,000382,8309,643Feb 10 04:45 PM
MURPHY ANDREW JEVP ResearchJan 27Sale340.918,0002,727,27949,951Jan 28 05:06 PM
Fenimore Christopher R.VP ControllerJan 24Option Exercise30.6350015,31513,097Jan 27 04:04 PM
SING GEORGE LDirectorJan 02Option Exercise24.4115,000366,150130,095Jan 06 04:02 PM
SING GEORGE LDirectorJan 02Sale371.9815,0005,579,700115,095Jan 06 04:02 PM
Fenimore Christopher R.VP ControllerDec 20Option Exercise30.6340012,25212,597Dec 23 04:02 PM
BROWN MICHAEL SDirectorDec 13Option Exercise273.674,0001,094,6804,323Dec 13 04:07 PM
VAGELOS P ROYChairman of the BoardDec 13Sale376.0451,84219,494,489304,485Dec 13 05:43 PM
BROWN MICHAEL SDirectorDec 13Sale373.994,0001,495,968323Dec 13 04:07 PM
Fenimore Christopher R.VP ControllerDec 13Sale376.141,682632,66512,197Dec 13 06:03 PM
VAGELOS P ROYChairman of the BoardDec 12Option Exercise21.25107,6552,287,669412,140Dec 13 05:43 PM
YANCOPOULOS GEORGEPresident and CSODec 12Option Exercise21.25245,2955,212,519521,876Dec 13 04:44 PM
SCHLEIFER LEONARD SPresident & CEODec 12Option Exercise21.25312,4006,638,500571,708Dec 13 04:05 PM
Fenimore Christopher R.VP ControllerDec 12Option Exercise52.033,100161,29315,297Dec 13 06:03 PM
GOLDSTEIN JOSEPH LDirectorNov 27Option Exercise33.421,00033,42011,323Dec 02 04:03 PM
GOLDSTEIN JOSEPH LDirectorNov 27Sale370.001,000370,00010,323Dec 02 04:03 PM
STAHL NEILEVP Research and DevelopmentNov 26Sale364.074,0061,458,46722,455Nov 26 04:29 PM
STAHL NEILEVP Research and DevelopmentNov 25Option Exercise52.0310,000520,30032,455Nov 26 04:29 PM
VAGELOS P ROYChairman of the BoardNov 25Sale363.8722,1498,059,412304,485Nov 26 04:02 PM
GOLDSTEIN JOSEPH LDirectorNov 22Option Exercise33.421,00033,42011,323Nov 22 04:07 PM
VAGELOS P ROYChairman of the BoardNov 22Option Exercise21.2546,138980,433386,716Nov 26 04:02 PM
GOLDSTEIN JOSEPH LDirectorNov 22Sale360.001,000360,00010,323Nov 22 04:07 PM
GOLDSTEIN JOSEPH LDirectorNov 21Option Exercise33.421,00033,42011,323Nov 22 04:07 PM
GOLDSTEIN JOSEPH LDirectorNov 21Sale350.001,000350,00010,323Nov 22 04:07 PM
BROWN MICHAEL SDirectorNov 12Option Exercise273.674,5001,231,5154,823Nov 13 04:11 PM
BROWN MICHAEL SDirectorNov 12Sale349.004,5001,570,500323Nov 13 04:11 PM
GOLDSTEIN JOSEPH LDirectorNov 08Sale340.441,000340,44010,323Nov 08 05:02 PM
STAHL NEILEVP Research and DevelopmentNov 08Sale338.527,3642,492,88822,455Nov 12 04:05 PM
VAGELOS P ROYChairman of the BoardMay 24Option Exercise21.25153,7923,268,080468,669May 29 04:16 PM
GOLDSTEIN JOSEPH LDirectorMay 15Sale305.931,000305,93011,323May 15 08:42 PM
STAHL NEILEVP Research and DevelopmentMay 14Sale305.749,8533,012,48322,450May 15 04:02 PM
STAHL NEILEVP Research and DevelopmentMay 13Option Exercise52.0325,0001,300,75047,450May 15 04:02 PM
Fenimore Christopher R.VP ControllerApr 18Option Exercise21.253507,4387,446Apr 18 07:04 PM
SCHLEIFER LEONARD SPresident & CEOMar 21Option Exercise21.251002,125424,062Mar 22 04:03 PM